Pioneering long-term maintenance data for plaque psoriasis

LEO Pharma A/S recently presented results from the Phase 3 PSO-LONG clinical trial comparing the efficacy and safety of twice-weekly calcipotriol and betamethasone dipropionate cutaneous foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.

Results were presented as ePosters online at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.

Calcipotriol and betamethasone dipropionate cutaneous foam met the primary endpoint in the PSO-LONG trial by prolonging time to first relapse versus foam vehicle (56 days vs. 30 days) – the number of days until 50 per cent of patients experienced first relapse.

“The year-long, first of its kind PSO-LONG study provides new data for the long-term maintenance treatment of adults with plaque psoriasis,” said Prof Richard Warren, Consultant Dermatologist of Salford Royal NHS Foundation Trust and the University of Manchester, UK.

“The data shows that calcipotriol and betamethasone dipropionate cutaneous foam met the trial’s primary endpoint, both reducing relapses and increasing the number of relapse-free days compared to foam vehicle.

“This is positive news for both clinicians and patients when considering management regimens for psoriasis due to it being a chronic condition that people typically live with for many years, if not decades. More long-term treatment options are essential for optimal outcomes.”

“Our vision in psoriasis is to continue to enhance the range of prescription solutions that we provide for patients with all severities of psoriasis by continual development of our portfolio such as we have done here with the PSO-LONG study,” said Amit Aggarwal, Medical Director UK/IE, LEO Pharma.

Use of twice weekly calcipotriol and betamethasone dipropionate cutaneous foam as a long-term maintenance treatment is investigational and is not approved in any country, and safety and efficacy are currently being evaluated by regulatory authorities.